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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) has been shown to be selective in the induction of apopto-
sis in cancer cells withminimal toxicity to normal tissues. However,
not all cancers are sensitive to TRAIL-mediated apoptosis. Thus,
TRAIL-resistant cancer cells must be sensitized first to become
responsive to TRAIL. In this study, we observed that pretreatment
by acetylsalicylic acid (ASA) augmented TRAIL-induced apoptotic
death in human prostate adenocarcinoma LNCaP and human colo-
rectal carcinomaCX-1 cells.Western blot analysis showed that pre-
treatment of ASA followed by TRAIL treatment activated caspases
(8, 9, and3) and cleavedpoly(ADP-ribose) polymerase, thehallmark
feature of apoptosis. Most interestingly, at least 12 h of pretreat-
ment with ASA was prerequisite for promoting TRAIL-induced
apoptosis and was related to down-regulation of BCL-2. Biochemi-
cal analysis revealed that ASA inhibited NF-B activity, which is
known to regulate BCL-2 gene expression, by dephosphorylating
IB- and inhibiting IKK activity but not by affecting the HER-2/
neuphosphatidylinositol 3-kinase-Akt signal pathway.Overexpres-
sion of BCL-2 suppressed the promotive effect of ASA on TRAIL-
induced apoptosis and changes in mitochondrial membrane
potential. Taken together, our studies suggested that ASA-pro-
moted TRAIL cytotoxicity is mediated through down-regulating
BCL-2 and by decreasing mitochondrial membrane potential.
Tumor cells develop resistance to apoptotic stimuli induced by vari-
ous therapeutic agents, such as drugs, irradiation, and immunotherapy,
because most of their primary cytotoxic effects are through apoptosis
(1, 2). After the initial response to these therapies, tumor cells develop
resistance and/or are selected for resistance to apoptosis. Therefore,
new therapeutic strategies are needed to reverse resistance to apoptosis.
Recent studies have also revealed that TRAIL,2 which is constitutively
expressed on murine natural killer cells in the liver, plays an important
role in surveillance of tumor metastasis (3). The apoptotic signal of
TRAIL is transduced by binding to the death receptors TRAIL-R1
(DR4) and TRAIL-R2 (DR5), which are members of the tumor necrosis
factor- receptor superfamily. Both DR4 and DR5 contain a cytoplas-
mic death domain that is required for TRAIL receptor-induced apopto-
sis. TRAIL also binds to TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2),
which act as decoy receptors by inhibiting TRAIL signaling (4–7).
Unlike DR4 and DR5, DcR1 does not have a cytoplasmic domain, and
DcR2 retains a cytoplasmic fragment containing a truncated form of the
consensus death domain motif (8). Tumor necrosis factor-related apo-
ptosis-inducing ligand (TRAIL) is a cytotoxic molecule that has been
shown to exert, selectively, anti-tumor cytotoxic effects both in vitro
and in vivo with minimal toxicity to normal tissues (9, 10).
TRAIL has been considered a new therapeutic agent, and preclinical
studies demonstrate its antitumor activity alone or in combination with
drugs (10–13). However, many tumor cells have been shown to be
resistant to TRAIL (14, 15). Several researchers have reported that
TRAIL resistance can be overcome by various sensitizing agents like
chemotherapeutic drugs (16, 17), cytokines (18), and matrix metallo-
protease inhibitors (19) that are able to render TRAIL-resistant tumor
cells sensitive to TRAIL apoptosis.
In recent studies, nonsteroidal anti-inflammatory drugs (NSAIDs),
such as acetylsalicylic acid (aspirin; ASA), have been used as chemopre-
ventive agents of cancers to induce apoptosis or to reduce the incidence
of tumor formations in a variety of organs, i.e. colon (20), lung (21),
stomach (22), and colorectum (23). ASA is known to act by directly
suppressing the cyclooxygenase enzyme (COX-1 and COX-2), the rate-
limiting enzyme catalyzing the biosynthesis of prostaglandins, thereby
blocking the production of proinflammatory prostaglandins. ASA was
also shown to be effective in the inhibition of ultraviolet radiation and
carcinogen-induced tumor formations in animal models (24, 25).
In this study, we examined whether ASA in combination with TRAIL
increases TRAIL-induced apoptotic death in TRAIL-resistant human
cancer cells. We hypothesized that pretreatment with ASA enhances
TRAIL-induced apoptosis by promoting the mitochondria-dependent
apoptotic pathway. Our studies demonstrate that ASA augments
TRAIL-induced apoptosis by down-regulating BCL-2 gene expression
and by decreasing mitochondrial membrane potential, which subse-
quently leads to an increase in caspase activation.
EXPERIMENTAL PROCEDURES
Reagents—ASA, NS-398, indomethacin, sulindac sulfide, and car-
bonyl cyanide p-trifluoromethoxyphenylhydrazonewere obtained from
Sigma. Tetramethylrhodamine methyl ester (TMRM) was purchased
from Molecular Probes (Eugene, OR). Anti-Bcl-XL, anti-phospho(Tyr-
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508)-PI3K, anti-caspase-3, anti-caspase-9, anti-histone H1, anti-IKK,
and anti-IKK antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Anti-HER-2/neu antibody was purchased from
DakoCytomation (Carpinteria, CA). Anti-DR5 and anti-DcR2 bodies
were purchased from StressGen (Victoria, British Columbia, Canada).
Anti-DR4 antibody, anti-caspase-8 antibody, and GST-IB protein
were purchased from Upstate Biotechnology (Lake Placid, NY). Anti-
COX-2 antibody was purchased from Cayman Chemical (Ann Arbor,
MI). Anti-phospho(Tyr-1248)-HER-2/neu, anti-phospho(Ser-473)-
Akt, anti-Akt, anti-phospho(Ser-32)-IB-, anti-IB-, anti-phos-
pho(Ser-241)-PDK-1, and anti-PDK-1 antibodies were purchased from
Cell Signaling (Beverly, MA). Anti-cIAP-1 and anti-cIAP-2 antibodies
were purchased from R&D Systems (Minneapolis, MN). Anti-FLIP
antibody was purchased from Calbiochem. Anti-PARP was purchased
fromBiomol. Anti-Bcl-2 and anti-actin antibodieswere purchased from
ICN (Costa Mesa, CA).
Cell Culture and Survival Assay—Human prostate adenocarcinoma
LNCaP and DU-145 cell lines, human colorectal carcinoma CX-1 cell
line, and normal prostate YPEN cell line were obtained from the Amer-
ican Tissue Type Culture Collection (Manassas, VA). LNCaP, CX-1,
and YPEN cells or DU-145 cells were cultured in RPMI 1640 medium
(Invitrogen) or Dulbecco’s modified Eagle’s medium (Invitrogen),
respectively, with 10% fetal bovine serum (HyClone, Logan, UT), 1 mM
L-glutamine, and 26mM sodium bicarbonate formonolayer cell culture.
The dishes containing cells were kept in a 37 °C humidified incubator
with amixture of 95% air and 5%CO2. One day prior to the experiment,
cells were plated in 60-mm dishes. For trypan blue exclusion assay (26),
trypsinized cells were pelleted and resuspended in 0.2ml ofmedium, 0.5
ml of 0.4% trypan blue solution, and 0.3ml of phosphate-buffered saline
solution (PBS). The samples weremixed thoroughly, incubated at room
temperature for 15 min, and examined under a light microscope. At
least 300 cells were counted for each survival determination.
Production of Recombinant TRAIL—A human TRAIL cDNA frag-
ment (amino acids 114–281) obtained byRT-PCRwas cloned into pET-
23d (Novagen, Madison, WI) plasmid, and His-tagged TRAIL protein
was purified using the QIAexpress protein purification system (Qiagen,
Valencia, CA).
TUNEL Assay—For detection of apoptosis by the TUNEL method,
cells were plated in slide chambers. After treatment, cells were fixed
with 70% ethanol in PBS. Cells were washed once, permeabilized by
incubating with 100 l of 0.1% Triton X-100, 0.1% sodium citrate, and
thenwashed twice in PBS. TheTUNEL reactionwas carried out at 37 °C
for 1 h with 0.3 nmol of fluorescein isothiocyante-12-dUTP, 3 nmol of
dATP, 2 l of CoCl2, 25 units of terminal deoxynucleotidyltransferase,
and TdT buffer (30 mM Tris, pH 7.2, 140 mM sodium cacodylate) in a
total reaction volume of 50l. The reaction was stopped with 2l of 0.5
M EDTA. Cells were observed under a fluorescence microscope.
RNA Interference by siRNA of COX-2—Todown-regulate theCOX-2,
COX-2 siRNA (Santa Cruz Biotechnology) was used.COX-2 siRNAwas
transfected into LNCaP cells and incubated for 36 h. The interference of
COX-2 protein expression was confirmed by immunoblot using anti-
COX-2 antibody (Cayman Chemical).
Transfection—In order to generate Bcl-2 overexpressing LNCaP cells
and CX-1 cells, cells were transfected with pcDNA3-Bcl-2 or
pcDNA3-neo using Lipofectamine Plus (Invitrogen). Transfected cells
were selected for 3weeks in growthmediumcontaining 0.5mg ofG-418
(geneticin; Invitrogen) per ml. The clone expressing the highest level of
Bcl-2 was used for this study. The expression level was determined by
immunoblot analysis.
FIGURE 1. Effect of pretreatment of acetylsali-
cylic acid on TRAIL-induced cytotoxicity in
human prostate adenocarcinoma LNCaP cells.
A, cells were pretreated with various concentra-
tions of ASA (0.01–1mM) for 20 h and treatedwith/
without 200 ng/ml TRAIL for 4 h. Cell survival was
determined by the trypan blue exclusion assay.
Error bars represent the means  S.E. from three
separate experiments. B, cells were pretreated
with 1 mM ASA for 20 h and treated with/without
various concentrations of TRAIL (1–200 ng/ml) for
4 h. Cell survival was determined by the trypan
blue exclusion assay. Error bars represent the
means  S.E. from three separate experiments.
C, cellswerepretreatedwith 1mMASA for 20h and
treatedwith/without 200ng/ml TRAIL for 4h.After
treatment, apoptosis was detected by the TUNEL
assay. Apoptotic cells are indicated by arrows.
a, untreated control; b, ASA only; c, TRAIL only;
d, ASA3 TRAIL.
Aspirin and TRAIL-induced Apoptosis
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Protein Extracts and PAGE—Cells were lysed with 1 Laemmli lysis
buffer (2.4 M glycerol, 0.14 M Tris, pH 6.8, 0.21 M SDS, 0.3 mM brom-
phenol blue) and boiled for 10 min. Protein content was measured with
BCA Protein Assay Reagent (Pierce). The samples were diluted with 1
lysis buffer containing 1.28 M-mercaptoethanol, and equal amounts of
protein were loaded on 8–12% SDS-polyacrylamide gels. SDS-PAGE
analysis was performed according to Laemmli (27) using a Hoefer gel
apparatus.
Immunoblot Analysis—Proteins were separated by SDS-PAGE and
electrophoretically transferred to nitrocellulose membrane. The nitro-
cellulosemembranewas blockedwith 5%nonfat drymilk in PBS/Tween
20 (0.1%, v/v) at 4 °C overnight. The membrane was incubated with
primary antibody (diluted according to themanufacturer’s instructions)
for 2 h. Horseradish peroxidase-conjugated anti-rabbit or anti-mouse
IgG was used as the secondary antibody. Immunoreactive protein was
visualized by the chemiluminescence protocol (ECL, Amersham
Biosciences).
In Vitro Kinase Assay—For immunocomplex kinase assay, cells were
lysedwith 500l of buffer A (20mMTris-HCl, pH 7.5, 1%TritonX-100,
0.5% deoxycholate, 5mMEGTA, 150mMNaCl, 10mMNaF, 1mMDTT,
1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and
protein inhibitor mixture solution (Sigma)). Cell lysates were immuno-
precipitated with anti-IKK or anti-IKK antibody. Immune com-
plexes werewashed twicewith buffer B (150mMNaCl, 20mMTris-HCl,
pH 7.5, 5 mM EGTA, 0.5 mM DTT, 1 mM Na3VO4, and 1 mM phenyl-
methylsulfonyl fluoride) at 4 °C and then incubatedwith 2g of purified
GST-IB protein (Upstate Biotechnology) in the presence or absence
of 1mMASA in a volume of 50l of a kinase buffer (100MATP, 20mM
Tris-HCl, pH 7.5, 20 mM MgCl2, 0.1 mM EDTA) for 30 min at 30 °C.
Thereafter, the sample was subjected to SDS-PAGE, and the phospho-
rylation of GST-IB was analyzed by anti-phospho-IB antibody
(Cell Signaling).
Measurement of Mitochondrial Membrane Depolarization—The
mitochondria-specific dye TMRM (Molecular Probe, Eugene, OR) was
used to measure the mitochondrial potential. CX-1 cells were grown in
6-well plates and were pretreated with 1 mM aspirin in the presence or
absence of TRAIL (200 ng/ml). After treatment, the cells were collected,
washed in PBS, and resuspended in 500 l of FASC buffer. Cells were
incubated for 20 min with 200 nM TMRM (Molecular Probe) at 4 °C in
the dark, washed in cold PBS twice, and then resuspended in 500 l of
PBS buffer. The cells were visualized by flow cytometry. Positive sam-
ples were stained with carbonyl cyanide p-trifluoromethoxyphenylhy-
drazone (mitochondrial membrane-depolarized inducer), and the sur-
face markers were analyzed by an EPICS XL-MCL flow cytometer with
a single argon laser at 488 nm (Beckman Coulter, Inc., Hialeah, FL).
Isolation of Nuclear Proteins—Nuclear extracts were prepared by the
modified procedure of Dignam et al. (28). Following treatment with
ASA for 20 h, LNCaP cells were washed three times with PBS and
incubated on ice for 15 min in hypotonic buffer A (10 mmol/liter
HEPES, pH 7.9, 10 mmol/liter KCl, 0.1 mmol/liter EDTA, 0.1 mmol/
liter EGTA, 1 mmol/liter DTT, 0.5 mmol/liter phenylmethylsulfonyl
fluoride, and 0.6% Nonidet P-40). Cells were vortexed gently for lysis,
and the nuclei were separated from the cytosol by centrifugation at
12,000  g for 1 min. Nuclei were resuspended in buffer C (20 mmol/
liter HEPES, pH 7.9, 25% glycerol, 0.4 mol/liter NaCl, 1 mmol/liter
EDTA, 1 mmol/liter EGTA, 1 mmol/liter DTT, and 0.5 mmol/liter
phenylmethylsulfonyl fluoride) and shaken for 30 min at 4 °C. Nuclear
extracts were obtained by centrifugation at 12,000  g, and protein
concentration was measured by Bradford assay (Bio-Rad). NF-B in
nuclear extracts was detected by Western blotting as described above.
FIGURE 2. Effect of pretreatment of acetylsalicylic acid on TRAIL-induced proteo-
lytic cleavage of PARP and activation of caspases in LNCaP (A), DU-145 (B), or YPEN
(C) cells. Cells were pretreated with various concentrations of ASA (1–10 mM) for 20 h,
treated with/without TRAIL (200 ng/ml in LNCaP and YPEN, 50 ng/ml in DU-145) for
4 h, and then harvested. Cell lysates were subjected to immunoblotting for PARP,
caspase-8, caspase-9, or caspase-3. Antibody against caspase-8 detects inactive form
(55 kDa) and cleaved intermediates (41 and 43 kDa). Anti-caspase-9 antibody detects
both inactive form (48 kDa) and cleaved intermediate (37 kDa). Anti-caspase-3 anti-
body detects inactive form (32 kDa) and cleaved active form (17 kDa). Immunoblots
of PARP show the 116-kDa PARP and the 85-kDa apoptosis-related cleavage frag-
ment. Actin was used to confirm the amount of proteins loaded in each lane. Con,
control; Casp, caspase.
Aspirin and TRAIL-induced Apoptosis
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Electrophoretic Mobility Shift Assay—LNCaP cells were treated with
various concentrations of ASA (0.01–1 mM) or 200 ng/ml TRAIL for
20 h, and nuclear extract was prepared as described above. The nuclear
extract (10 g of protein) was incubated with binding buffer (20 mM
HEPES, pH 7.6, 1 mM EDTA, 1 mM ammonium sulfate, 1 mM DTT, 30
mM KCl, 0.2% Tween 20) and 1 g of poly(dI-dC) for 10 min on ice.
Biotin-labeled probe NF-B-specific oligonucleotide (5-AGTT-
GAGGGGACTTTCCCAGGC-3) was used. The reaction was incu-
bated at room temperature for 30min. The negative control consisted of
free probe only. A competition control was set up by adding non-biotin-
labeled cold probe to the reaction. The samples separated on a 6%native
polyacrylamide gel in 0.5% TBE for 50 min at 120 V. The samples were
then transferred in 0.5% TBE onto a nylon membrane at 300 mA for 40
min. After transfer, the samplewas fixed on themembrane byUVcross-
linking. The membrane was first blocked with 1% blocking reagent
(Roche Applied Science) at room temperature for 30 min. The biotin-
labeled probe was then detected with streptavidin-horseradish peroxi-
dase diluted 1: 20,000 (Pierce). After washing three times and equilibrat-
ing in buffer, the membrane was overlaid with lumino/enhancer and
substrate for 5 min. The image was acquired using a Kodak X-Omat
2000A (Eastman Kodak, Rochester, NY).
Flow Cytometry—Cells were treated with ASA for the indicated time
points with or without TRAIL. After washing, cells were blocked for 30
min with 1% bovine serum albumin in PBS. Cells were then incubated
with 1 g of primary antibodies to DR4 or DR5 (Alexis) in 1% bovine
serum albumin for 30 min followed by washing with PBS. Finally, cells
were incubated with Alexa 488-conjugated goat anti-mouse IgG
(Molecular Probe) for 30min. After washing, the cells were analyzed on
a FACScan flow cytometer.Matched isotype using control IgG antibod-
ies was included.
FIGURE 3. Effect of pretreatment of acetylsali-
cylic acid on TRAIL-induced PARP cleavage in
LNCaP cells. A, cells were pretreated with 1 mM
ASA for various times (0–24 h) and treated with
200 ng/ml TRAIL for 4 h. B, cells were pretreated
with 1 mM ASA for 20 h and treated with various
concentrations of TRAIL (1–200 ng/ml) for 4 h.
C, cells were treated with various concentrations
of ASA (0.01–1 mM) for 20 h and treated with 200
ng/ml TRAIL for 4 h. Equal amounts of protein (20
g) were separated by SDS-PAGE and immuno-
blottedwith anti-PARP antibody. Actin is shownas
an internal standard. Lane C, control.
FIGURE 4. TRAIL in combination with acetylsali-
cylic acid without pretreatment of acetylsali-
cylic acid has no effect on TRAIL-induced apo-
ptosis in LNCaP cells. A, cells were treated with
200ng/ml TRAIL in combinationwith 1mMASA for
various times (0–24 h). Cell survival was deter-
mined by the trypan blue exclusion assay. Error
bars represent the means S.E. from three sepa-
rate experiments. B, equal amounts of protein (20
g) were separated by SDS-PAGE and immuno-
blottedwith anti-PARP antibody. Actin is shownas
an internal standard. Lane C, control.
FIGURE 5. Role of COX in acetylsalicylic acid-induced TRAIL cytotoxicity. A–C, LNCaP
cellswere pretreatedwith 1mMASA (A T), or various concentrations of sulindac sulfide
(Sul  TRAIL), NS-398 (NS-398  TRAIL), or indomethacin (Indo  TRAIL) for 20 h and
treatedwith200ng/ml TRAIL for 4h. Equal amountsofprotein (20g)were separatedby
SDS-PAGEand immunoblottedwith anti-PARPantibody.D, LNCaPcellswere transfected
withCOX-2 siRNAormock siRNA and incubated for 36 h. Cellswere pretreatedwith 1mM
ASA for 20 h and treated with 200 ng/ml TRAIL for 4 h. Equal amounts of protein (20g)
were separated by SDS-PAGE and immunoblotted with anti-PARP, anti-COX-2, or anti-
actin antibody. C, untreated control cells; T, TRAIL-treated cells; AT, ASA- and TRAIL-
treated cells.
Aspirin and TRAIL-induced Apoptosis
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RT-PCR Analysis of Bcl-2 mRNA Levels—Total cellular RNA was
extracted using the Trizol method (Invitrogen) according to the manu-
facturer’s instructions. For each RT-PCR, 1 g of total RNA was used
with Novagen One-step RT-PCR kit (EMD Bioscience). The following
sense and antisense primers were used at 0.5 M for each: Bcl-2 primer,
sense, 5-CGACGACTTCTCCCGCCGCTACCGC-3, and antisense,
FIGURE 6. Effect of pretreatment of acetylsali-
cylic acid in combination with TRAIL on intra-
cellular levels of TRAIL receptors (A), expres-
sion of functional TRAIL receptors on
membrane (B), or anti-apoptotic proteins (C) in
LNCaP cells. A and B, cells were pretreated with
various concentrations of ASA (1–10 mM) for 20 h
and treated with/without 200 ng/ml TRAIL for 4 h.
A, equal amounts of protein (20 g) were sepa-
rated by SDS-PAGE and immunoblottedwith anti-
DR-5, anti-DR-4, anti-DcR2, or anti-actin antibody.
Actinwas shown as an internal standard.Con, con-
trol. B, cells were stained with Alexa 488-conju-
gated antibodies and analyzed with a FACScan
flow cytometer. Staining with isotype-matched
control IgG represents negative control. C, cells
were treated for various times (4–24 h) with 1 mM
ASA and harvested. Equal amounts of protein (20
g) were separated by SDS-PAGE and immuno-
blotted with anti-FLIP, anti-IAP-1, anti-IAP-2, anti-
Bcl-XL, anti-Bcl-2, or anti-actin antibody. Actin is
shown as an internal standard.
FIGURE 7. Acetylsalicylic acid-mediated down-
regulation of Bcl-2 expression in LNCaP or
DU-145 cells. A, cells were treated with various
concentrations of ASA (0.01–1 mM) or 200 ng/ml
TRAIL for 20 h for LNCaP cells or 10 ng/ml TRAIL for
20 h forDU-145 cells. Equal amounts of protein (20
g) were separated by SDS-PAGE and immuno-
blotted with anti-Bcl-2 or anti-actin antibody.
Actinwas shownas an internal standard. B,RT-PCR
analysis was performed for detecting BCL-2 or
glyceraldehyde-3-phosphate dehydrogenase
(G3PDH) expression in LNCaP cells. Glyceralde-
hyde-3-phosphate dehydrogenase is shown as an
internal standard. C, Northern blot analysis was
performed for detecting Bcl-2. Total electro-
phoretically fractionated RNA was probed with
the BCL-2 cDNA fragment (upper panel). The
ethidium bromide-stained ribosomal RNAs are
shown as a loading control (lower panel). Con,
control.
Aspirin and TRAIL-induced Apoptosis
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5-CCGCATGCTGGGGCCGTACAGTTCC-3; glyceraldehyde-3-
phosphate dehydrogenase primer, sense, 5-TCCACCACCCTGTTG-
CTGTA-3, and antisense, 5-ACCACAGTC-CATGCCATCAC-3.
The reaction conditions were 40 cycles at reverse transcription at 60 °C
for 30min, initial PCR activation at 94 °C for 2min, denature at 94 °C for
1 min, anneal at 60 °C for 90 s, and final extension at 60 °C for 7 min.
After amplification, the products were resolved by electrophoresis on
1% agarose gel, stained with ethidium bromide, and photographed
under ultraviolet light.
Northern Blot Analysis—LNCaP cells were treated with either 200
ng/ml TRAIL or various concentrations of aspirin (0.01, 0.1, 0.5, and 1
mM) for 20 h. For Northern blot hybridization, total RNAs (10 g)
isolated from the above-treated cells were fractionated by electrophore-
sis in formaldehyde-1.2% agarose gels, blotted onto Nytran Plus
(Schleicher & Schuell), and hybridized with the 32P-labeled BCL-2
cDNA probe. The 448-bp BCL-2 cDNA probe was amplified by using
PCR with primers 5-CACCTGACCCTCCGCCAG-3 (forward) and
5-TGTTGACTTCACTTGTGGCCCAG-3 (reverse).
RESULTS
ASA Promotes TRAIL-induced Cytotoxicity—To investigate the
effect of ASA on TRAIL-induced cytotoxicity, human prostatic adeno-
carcinoma LNCaP cells were pretreated with ASA and treated with
TRAIL in the presence of ASA. Fig. 1, A and B, shows that little or no
cytotoxicity was observed with 1 mM ASA alone or 200 ng/ml TRAIL
alone. However, pretreatment of ASA promoted TRAIL-induced cyto-
toxicity that was dependent upon concentrations of ASA (Fig. 1A) and
TRAIL (Fig. 1B). Similar results were observed with TUNEL staining
(Fig. 1C). Data from TUNEL assays show that apoptotic cell death
occurred when LNCaP cells were pretreated with ASA followed by
TRAIL.
Effect of ASA on TRAIL-induced Apoptosis—Additional studies were
designed to examine whether pretreatment with ASA followed by treat-
ment with TRAIL causes PARP cleavage, the hallmark feature of apo-
ptosis, in prostate cancer LNCaP and DU-145 cells and normal prostate
YPEN cells. Fig. 2 shows that PARP (116 kDa) was cleaved yielding a
characteristic 85-kDa fragment in the presence of TRAIL (50–200
ng/ml) and ASA (1–10 mM) in prostate cancer cells, but not in normal
prostate cells. The cleavage of PARP was not observed by treatment
with ASA alone. These results were similar to the observations of cyto-
toxicity (Fig. 1,A and B).Western blot analysis shows that procaspase-8
(55 kDa) was cleaved to the intermediates (41 and 43 kDa) by pretreat-
ment with ASA and treatment with TRAIL in LNCaP andDU-145 cells.
The combined treatment of TRAIL andASA also resulted in an increase
in caspase-9 activation as well as caspase-3 activation in LNCaP and
DU-145 cells (Fig. 2, A and B). The precursor form of caspase-9 and -3
was cleaved to the active form of 37 and 17 kDa, respectively. ASA alone
did not activate caspases. We extended our studies to investigate a time
course and dose response on PARP cleavage. Fig. 3A shows that at least
12 h of pretreatment with ASA was required for PARP cleavage in the
presence of TRAIL. Fig. 3, B and C, shows that a minimal amount of 10
ng/ml TRAIL or 0.01 mM ASA was required for PARP cleavage in the
presence of 1 mM ASA or 200 ng/ml TRAIL, respectively, in LNCaP
cells. We further investigated whether treatment with ASA is a prereq-
uisite. Fig. 4 shows that combined treatment with TRAIL and ASA
without pretreatment with ASA caused little or no cytotoxicity and
PARP cleavage. Taken together, these results suggest that pretreatment
FIGURE 8. Effect of acetylsalicylic acid on the HER-2/neu-PI3K-Akt signal transduc-
tion pathway in LNCaP cells. Cells were treated with various concentrations of ASA
(0.01–1 mM) or 200 ng/ml TRAIL for 20 h. Equal amounts of protein (20 g) were sepa-
rated by SDS-PAGE and immunoblottedwith anti-HER-2/neu, anti-phospho-HER-2/neu,
anti-PI3K, anti-phospho-PI3K, anti-Akt, anti-phospho-Akt, or anti-actin antibody.
C, control.
FIGURE 9. Effect of acetylsalicylic acid on IKK
activity (A), IB- phosphorylation (B), or
NF-B (D and E) translocation in LNCaP cells,
and purity of the nuclear extracts (C). A, cells
were lysed, and IKK proteins were purified by
immunoprecipitation (IP). The purified IKK pro-
teinswere incubatedwith orwithout 1mMASA for
30 min at 4 °C, and in vitro kinase assay was per-
formed at 30 °C for 30 min with GST-IB- as sub-
strate.B, cellswere treatedwith various concentra-
tions of ASA (0.01–1 mM) or 200 ng/ml TRAIL for
20 h and lysed. Equal amounts of protein (20 g)
were separated by SDS-PAGE and immunoblotted
(IB) with anti-phospho-IB-, anti-IB-, or anti-
actin antibody. Lane C, control. C–E, cells were
treated with various concentrations of ASA
(0.01–1 mM) or 200 ng/ml TRAIL for 20 h, and
nuclear proteins were extracted (C). D, equal
amounts of nuclear protein (20 g) were sepa-
rated by SDS-PAGE and immunoblottedwith anti-
NF-B antibody. E, the nuclear extracts were incu-
batedwithbiotin-labeledoligonucleotide at room
temperature for 30 min. Gel mobility shift assays
were performed as described under the “Experi-
mental Procedures.”
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with ASA for 12 h is essential for inducing apoptotic death in the pres-
ence of TRAIL.
Role of COX in TRAIL-induced Apoptosis—It is well known that ASA
inhibits only COX-1 at low concentrations (IC50  44 M) but both
COX-1 and COX-2 at higher concentrations (IC50 1100M) (29). To
examine whether the promotive effect of ASA on TRAIL-induced apo-
ptosis is mediated through inhibiting COX, LNCaP cells were pre-
treatedwith variousNSAIDs and then treatedwithTRAIL. UnlikeASA,
Fig. 5,A–C, shows that no significant cleavage of PARPwas observed by
treatment with various concentrations of sulindac sulfide (IC50  1.02
M for COX-1 and IC50  10.43 M for COX-2), NS-398 (a selective
COX-2 inhibitor; IC50  4.81 M for COX-1 and IC50  0.47 M for
COX-2), or indomethacin (a nonselective COX inhibitor; IC50  0.16
M for COX-1 and IC50 0.46 M for COX-2). To confirm our obser-
vations, cells were transfected with COX-2 siRNA or mock siRNA. Fig.
5D shows that the expression of COX-2 was effectively inhibited by
siCOX-2. However, knock-down of COX-2 expression did not promote
TRAIL-induced apoptosis. Nonetheless, pretreatment with ASA pro-
moted TRAIL-induced apoptosis regardless of the presence or the
absence of COX-2. These results suggest that COX is not involved in
ASA-promoted TRAIL cytotoxicity.
Effect of ASA on the Level of TRAIL Receptor Family and Anti-apo-
ptotic Proteins—It is well known that TRAIL can interact with death
receptors (DR4 and DR5), which trigger apoptotic signals (4). Such sig-
nals may be blocked by expression of the antagonistic decoy receptors
(DcR1 and DcR2). Previous studies demonstrate that increased DR5
levels are induced by chemotherapeutic agents (30). Thus, we examined
whether pretreatment with ASA affects the level of TRAIL receptors
and anti-apoptotic proteins, and consequently promotes apoptosis by
treatment with TRAIL. LNCaP cells were pretreated with ASA (1–10
mM) and treated with 200 ng/ml TRAIL in the presence of ASA. Data
from Western blot analysis reveal that ASA treatment did not signifi-
cantly alter the total cellular levels of the TRAIL receptors (DR4, DR5,
andDcR2) and anti-apoptotic proteins (FLIPL, FLIPS, IAP-1, IAP-2, and
Bcl-XL) (Fig. 6, A and C). Data from flow cytometric analysis show that
TRAIL induced surface expression of DR5 but not DR4 (Fig. 6B). How-
ever, ASA treatment did not enhance the DR5 expression. Most inter-
estingly, ASA treatment resulted in a decrease in the level of Bcl-2 (Fig.
6C). The reduction of Bcl-2 during treatment with 1 mM ASA was
dependent upon exposure time (Fig. 6B). To confirm the effect of ASA
on BCL-2 gene expression, LNCaP or DU-145 prostatic cancer cells
were treated with various concentrations of ASA, and expression of
BCL-2was examined. Fig. 7A shows that ASA reduced the level of Bcl-2
in both cell lines. Data from RT-PCR and Northern blot assay in Fig. 7,
B andC, show that the level ofBCL-2mRNAwas significantly decreased
during treatment with ASA. The reduction of BCL-2 mRNA was
dependent upon ASA concentration. These results suggest that the
reduction of Bcl-2 levels during treatment with ASA was because of
suppression of BCL-2 gene transcription.
FIGURE 10. Overexpression of BCL-2 effectively inhibits potentiation of TRAIL-in-
duced apoptosis by acetylsalicylic acid in LNCaP cells. A, immunoblot of BCL-2
expression in control vector-transfected (LNCaP/neo) and BCL-2 transfected (LNCaP/
Bcl-2) single cell clones of LNCaP cells.Con,untransfectedparental control cells.B,paren-
tal control, LNCaP/neo, or LNCaP/Bcl-2 cells were treated with 200 ng/ml TRAIL for 4 h
with/without pretreatment of 1 mM ASA for 20 h and then harvested. Cell lysates were
subjected to immunoblotting for caspase (Casp)-9, caspase-3, PARP, or actin. Actin is
shown as an internal standard.
FIGURE 11. Overexpression of BCL-2 effectively
inhibits augmentation of TRAIL-induced apop-
totic death by acetylsalicylic acid in colorectal
carcinoma CX-1 cells. A, immunoblot of BCL-2
expression in control vector-transfected (CX-1/
neo) and BCL-2-transfected (CX-1/Bcl-2) single cell
clones of CX-1 cells. Con, untransfected parental
control cells. B, cells were pretreated with 1 mM
ASA for 20 h and treated with 200 ng/ml TRAIL for
4 h. Cell survival was determined by the trypan
blue exclusion assay. Error bars represent the
mean  S.E. from three separate experiments.
C, parental control, CX-1/Neo, or CX-1/Bcl-2 cells
were treated with 200 ng/ml TRAIL for 4 h with/
without pretreatment of 1 mM ASA for 20 h and
then harvested. Cell lysates were subjected to
immunoblotting for caspase (Casp)-9, PARP, or
actin. Actin is shown as an internal standard.
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Effect of ASA on the HER-2/neu-PI3K-Akt-NF-B Signal Transduc-
tion Pathway—It is well known that BCL-2 expression is regulated by
NF-B, a dimeric transcription factor (31). We postulated that ASA
inhibits NF-B activity, which subsequently decreases transcription of
BCL-2. To examine this possibility, the effect of ASAon upstream signal
transduction of NF-B was investigated. Fig. 8 shows that ASA treat-
ment did not change the level of HER-2/neu, PI3K, and Akt or alter the
phosphorylation of these proteins. In contrast, ASA treatment inhibited
IKK activity, dephosphorylated IB-, increased the level of IB-,
and prevented NF-B nuclear translocation (Fig. 9). These results sug-
gest that ASA down-regulates BCL-2 gene expression by inhibiting the
IKK-IB--NF-B signal transduction pathway.
Role of Bcl-2 in ASA-enhanced TRAIL Cytotoxicity—To determine
whether ASA-mediated down-regulation of BCL-2 plays an important
role in the augmentation of TRAIL-induced apoptotic death, LNCaP
cells or human colorectal carcinoma CX-1 cells were stably transfected
with either an empty control vector (pcDNA 3-neo) or vector contain-
ing BCL-2 (pcDNA3-Bcl-2). Figs. 10 and 11 show that pretreatment
with ASA followed by treatment with TRAIL caused PARP cleavage,
activation of caspases, as well as cytotoxicity in control vector trans-
fected cells. However, overexpression of BCL-2 protected LNCaP and
CX-1 cells from ASA-enhanced TRAIL cytotoxicity. These results sug-
gest that ASA-promoted TRAIL cytotoxicity is mediated by down-reg-
ulating BCL-2.
Overexpression of BCL-2 Prevents Alteration of Mitochondrial Mem-
brane Potential by Treatment with ASA and TRAIL—Bcl-2 is an anti-
apoptotic protein that inhibits the release of cytochrome c from mito-
chondria into the cytoplasm, thereby down-regulation of BCL-2 may
promote intrinsic mitochondria-mediated apoptosis (32, 33). To inves-
tigate whether ASA disrupts mitochondrial membrane potential and
overexpression ofBCL-2 protects cells from this disruption, CX-1/Bcl-2
or CX-1/neo cells were pretreated with ASA and treated with TRAIL.
We used the mitochondria-specific dye TMRM to measure the mito-
chondrial membrane potential. Fig. 12 shows that overexpression of
BCL-2 inhibited the loss of mitochondrial membrane potential during
treatment with ASA alone or ASA in combination with TRAIL.
A Model for the Effect of ASA on the TRAIL-induced Apoptotic
Pathway—Fig. 13 shows a schematic diagramof amodel that is based on
the literature and our data. ASA blocks the Akt-NF-B survival signal
pathway by inhibiting IKK. The inhibition of this pathway results in
suppression of the expression of BCL-2, an anti-apoptotic molecule.
DISCUSSION
Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug
(NSAID) widely used for its anti-pyretic and analgesic properties. ASA
is also known to induce gastrointestinal side effects, mainly in the form
of gastric and duodenal ulcerations or erosions. However, epidemiolog-
ical findings have revealed thatASA reduces the risk of colorectal cancer
and adenoma (34, 35). In this study, we demonstrate that pretreatment
with ASA promotes TRAIL-induced apoptotic death. The enhance-
ment of apoptosis by treatment with ASA is probably because of down-
regulation ofBCL-2, activation of caspases, induction of conformational
change, translocation of Bax, and cytochrome c release (Figs. 2, 6, and 7)
(36–40). Our observations were similar to previous reports (41). Previ-
ous studies have shown that aspirin inhibits the transcription factor
FIGURE12.Effect ofBCL-2overexpressiononacetylsalicylic acidandTRAIL-induced
mitochondrial membrane perturbations. CX-1/neo (A) or CX-1/Bcl-2 (B) cells were
pretreated with 1 mM ASA for 20 h and treated with/without 200 ng/ml TRAIL for 4 h.
Mitochondrial membrane potential was assessed by flow cytometry using the fluores-
cent dye TMRM.
FIGURE 13. A schematic model for the effect of
acetylsalicylic acid on theTRAIL-inducedapop-
totic death signal pathway. PIP3, phosphatidyl-
inositol 3,4,5-triphosphate;PH, pleckstrinhomology.
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NF-B (42, 43), which is critical for the expression of several anti-apop-
totic genes including C-IAP1, C-IAP2, BCL-XL, FLIP, and BCL-2 (31,
44–46). The inhibition of NF-B activity is mediated through prevent-
ing the phosphorylation and degradation of the inhibitory subunit IB
(Fig. 9) (47). Although the expression of these Bcl-2 family and IAP
family proteins is known to be regulated by NF-B, our data show that
ASA inhibits preferentially BCL-2 gene expression (Fig. 6). Thus, a fun-
damental question that remains unanswered is how ASA inhibits selec-
tively the expression of the BCL-2 gene among BCL-2 family and IAP
family genes. It is well known that the NF-B family of proteins, includ-
ing NF-B1, NF-B2, RelA, RelB, and c-Rel, can form homo- and het-
erodimers in vitro, except for RelB. In mammals, the most widely dis-
tributed NF-B is a heterodimer composed of p50 and p65 (also called
RelA) subunits (48). NF-B activity is regulated by the IB family of
proteins that interacts with and sequesters the transcription factor in
the cytoplasm. IB proteins become phosphorylated by the multisub-
unit IKK complex, which subsequently targets IB for ubiquitination
and degradation by the 26 S proteasome (49). At this time only specu-
lations can be made concerning the role of NF-B in the down-regula-
tion of BCL-2 gene expression during treatment with ASA. One possi-
bility is that differential activation of NF-B may be responsible for
selective inhibition of BCL-2 gene expression. As mentioned above, the
inhibition of five members of the NF-B family may differ during treat-
ment with ASA, and this differential inhibition of the various members
of NF-B family causes a selective inhibition of BCL-2 gene expression
(50).We believe thatmany critical questions still remain to be answered
in order to understand the mechanisms of the regulation of BCL-2 gene
expression by ASA. However, this model will also provide a framework
for future studies.
Previous studies have shown that ASA inhibits tumor necrosis fac-
tor-- and interleukin-1-inducedNF-B activation and sensitizes HeLa
cells to apoptosis (51). In this study, we observed that ASA augments
TRAIL cytotoxicity in TRAIL-resistant LNCaP cells that contain high
levels of HER-2/neu. It is well known that HER-2/neu has an intrinsic
tyrosine kinase activity that activates PI3K in the absence of ligand (52).
PI3K consists of a regulatory subunit (p85) that binds to an activated
growth factor/cytokine receptor and undergoes phosphorylation,
which results in the activation of its catalytic subunit (p110) (53). PI3K
phosphorylates phosphoinositides at the 3-position of the inositol ring,
and its major lipid product is phosphatidylinositol 3,4,5-triphosphate
(54). Phosphatidylinositol 3,4,5-triphosphate facilitates the recruitment
of Akt to the plasma membrane through binding with the pleckstrin
homology domain of Akt (54). Akt is activated by phosphoinositide-de-
pendent kinase-1 (PDK1) through phosphorylation at threonine 308
and serine 473 (55). A number of pro-apoptotic proteins have been
identified as direct Akt substrates, including BAD, caspase-9, and Fork-
head transcription factors (56–61). The pro-apoptotic function of these
molecules is suppressed upon phosphorylation by Akt. Recent studies
also show that Akt induces the degradation of IB by promoting IKK
activity and subsequently stimulating the nuclear translocation of
NF-B (62). In this study, we have revealed that ASA does not affect the
HER-2/neu-PI3K-Akt signal transduction pathway (Fig. 8). However,
ASA can interrupt the Akt-NF-B signal transduction pathway by
inhibiting IKK activity (Fig. 9) (47). A previous study shows that 1 mM
aspirin treatment inhibits 75% of endogenous IKK kinase activity, even
though more than 90% of IKK activity is inhibited without altering
IKK activity in the presence of aspirin (47). These results suggest that
a small percentage of total IKK forms IKK homodimers that still
contain kinase activity in the presence of aspirin. In this study, we
believe that blockade of HER-2/neu-mediated survival signals by inhib-
iting IKK activity can sensitize TRAIL-resistant tumor cells. We also
believe that this study will provide information to improve the efficacy
of TRAIL-based clinical therapy.
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